@prefix this: <http://bio2rdf.org/drugbank:DB05775_nanopub.RAeThRURnF_AhyoXtl2S35FKc857RR6BUZmJlYR291bsM> .
@prefix sub: <http://bio2rdf.org/drugbank:DB05775_nanopub.RAeThRURnF_AhyoXtl2S35FKc857RR6BUZmJlYR291bsM#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.7720f136-841b-4851-a6e4-ad20a409a475> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix v: <http://bio2rdf.org/bio2rdf_vocabulary:> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:publicationInfo;
    a np:Nanopublication .
}

sub:assertion {
  d:DB05775 v:identifier "DB05775";
    v:namespace "drugbank";
    v:uri "http://bio2rdf.org/drugbank:DB05775";
    v:x-identifiers.org <http://identifiers.org/drugbank/DB05775>;
    dv:drugbank-id "DB05775";
    dv:x-cas <http://bio2rdf.org/cas:>;
    dct:description "CRx-401 is a novel insulin sensitizer designed to provide anti-diabetic activity without promoting weight gain. It consists of a low dose of the analgesic diflunisal in conjunction with a modified-release therapeutic dose of bezafibrate, an anti-cholesterol agent. In third-party clinical studies, the dose of bezafibrate contained in CRx-401 has been observed to have a positive impact on cellular pathways that influence glycemic and lipid profiles, and this dose has proven to be well tolerated in clinical trials. Unlike other NSAIDs, or non-steroidal anti-inflammatory drugs, the dose of diflunisal in CRx-401 has demonstrated in preclinical studies the ability to synergistically enhance the anti-diabetic effects of bezafibrate through novel disease-targeted mechanisms."@en;
    dct:identifier "drugbank:DB05775";
    dct:title "CRx-401"@en;
    a dv:Drug;
    rdfs:label "CRx-401 [drugbank:DB05775]"@en;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05775> .
}

sub:provenance {
  sub:assertion prov:wasDerivedFrom <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  
  dr:bio2rdf.dataset.drugbank.R3 dcat:distribution <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> .
  
  <http://download.bio2rdf.org/release/3/drugbank/drugbank.nq.gz> dct:created "2015-01-09T17:00:50-05:00"^^xsd:dateTime;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00> .
  
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip#retrieved-on:2014-11-12T07:57:03-05:00>
    pav:retrievedOn "2014-11-12T07:57:03-05:00"^^xsd:dateTime;
    prov:wasDerivedFrom <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> .
  
  <http://www.drugbank.ca/system/downloads/current/drugbank.xml.zip> prov:wasAttributedTo
      <http://drugbank.ca> .
}

sub:publicationInfo {
  sub:signature.MCwCFG6rs_E-y0YN npx:hasPublicKey "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";
    npx:hasSignature "MCwCFG6rs/E+y0YNa9UmHhDa6RLnFANOAhQ56AZGdKvosQC/oPW8x07+PIMHWg==";
    npx:signedBy instance: .
  
  this: dct:created "2018-03-30T11:10:51.943+02:00"^^xsd:dateTime;
    dct:license <https://creativecommons.org/licenses/by-nc/4.0/>;
    npx:hasSignatureElement sub:signature.MCwCFG6rs_E-y0YN;
    prov:wasGeneratedBy process: .
  
  instance: prov:specializationOf codebase:;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  
  process: dct:identifier "7720f136-841b-4851-a6e4-ad20a409a475";
    prov:used version:;
    prov:wasAssociatedWith instance:;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  
  version: dct:isVersionOf codebase:;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}